A Phase II study of Prolarix in HCC

• Research type

  Research Study

• Full title

  A Phase II study of the anti-tumour activity and safety of Prolarix in Hepatocellular Carcinoma (HCC)

• IRAS ID

  10279

• Contact name

  Daniel Palmer

• Contact email

  Daniel.Palmer@liverpool.ac.uk

• Sponsor organisation

  Protherics Medicines Development Ltd

• Eudract number

  2008-000912-34

• Clinicaltrials.gov Identifier

  NCT00746590

• Research summary

  Research Summary not published at request of researcher

• REC name

  West Midlands - Edgbaston Research Ethics Committee

• REC reference

  09/H1208/2

• Date of REC Opinion

  18 Mar 2009

• REC opinion

  Further Information Favourable Opinion